These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 9024721)

  • 1. Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors.
    Trendle MC; Moertel CG; Kvols LK
    Cancer; 1997 Feb; 79(4):830-4. PubMed ID: 9024721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic treatment with a long-acting somatostatin analogue in a patient with intestinal carcinoid tumor: occurrence of cholelithiasis.
    Roti E; Minelli R; Gardini E; Salvi M; Bianconi L; Balducci L; Manfredi A; Braverman LE
    J Endocrinol Invest; 1990 Jan; 13(1):69-72. PubMed ID: 2319110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regression of metastatic carcinoid tumors with octreotide therapy: two case reports and a review of the literature.
    Leong WL; Pasieka JL
    J Surg Oncol; 2002 Mar; 79(3):180-7. PubMed ID: 11870669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical review 23: The use of the long-acting somatostatin analog octreotide in the treatment of gut neuroendocrine tumors.
    Wynick D; Bloom SR
    J Clin Endocrinol Metab; 1991 Jul; 73(1):1-3. PubMed ID: 1646213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group.
    di Bartolomeo M; Bajetta E; Buzzoni R; Mariani L; Carnaghi C; Somma L; Zilembo N; di Leo A
    Cancer; 1996 Jan; 77(2):402-8. PubMed ID: 8625251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours.
    Arnold R; Trautmann ME; Creutzfeldt W; Benning R; Benning M; Neuhaus C; Jürgensen R; Stein K; Schäfer H; Bruns C; Dennler HJ
    Gut; 1996 Mar; 38(3):430-8. PubMed ID: 8675099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholelithiasis and acromegaly: therapeutic strategies.
    Montini M; Gianola D; Pagani MD; Pedroncelli A; Caldara R; Gherardi F; Bonelli M; Lancranjan I; Pagani G
    Clin Endocrinol (Oxf); 1994 Mar; 40(3):401-6. PubMed ID: 8187305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid.
    Raderer M; Kurtaran A; Scheithauer W; Fiebiger W; Weinlaender G; Oberhuber G
    Oncology; 2001; 60(2):141-5. PubMed ID: 11244329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of continuous subcutaneous infusion of octreotide on gallstone formation in acromegalic patients.
    Tauber JP; Poncet MF; Harris AG; Barthel HR; Simonetta-Chateauneuf C; Buscail L; Bayard F
    J Clin Endocrinol Metab; 1995 Nov; 80(11):3262-6. PubMed ID: 7593435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-standing malignant pancreatic carcinoid treated with octreotide.
    Varas-Lorenzo MJ
    Rev Esp Enferm Dig; 2010 Nov; 102(11):662-6. PubMed ID: 21142389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An important new treatment for carcinoid tumors and VIPomas.
    Oncology (Williston Park); 1988 Dec; 2(12):35-6. PubMed ID: 2856315
    [No Abstract]   [Full Text] [Related]  

  • 12. Use of octreotide acetate for control of symptoms in patients with islet cell tumors.
    Maton PN
    World J Surg; 1993; 17(4):504-10. PubMed ID: 8395751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors.
    Varker KA; Campbell J; Shah MH
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):661-8. PubMed ID: 17589846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas.
    Reubi JC; Kvols LK; Waser B; Nagorney DM; Heitz PU; Charboneau JW; Reading CC; Moertel C
    Cancer Res; 1990 Sep; 50(18):5969-77. PubMed ID: 2168286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Octreotide--a synthetic somatostatin.
    Med Lett Drugs Ther; 1989 Jul; 31(796):66-8. PubMed ID: 2567960
    [No Abstract]   [Full Text] [Related]  

  • 16. Octreotide LAR in carcinoid: how to dose?
    Yao JC; Kvols LK
    Pancreas; 2008 Oct; 37(3):337-8; author reply 338-9. PubMed ID: 18815562
    [No Abstract]   [Full Text] [Related]  

  • 17. Octreotide.
    Lamberts SW; van der Lely AJ; de Herder WW; Hofland LJ
    N Engl J Med; 1996 Jan; 334(4):246-54. PubMed ID: 8532003
    [No Abstract]   [Full Text] [Related]  

  • 18. Carcinoid of the pancreas.
    Migliori M; Tomassetti P; Lalli S; Casadei R; Santini D; Corinaldesi R; Gullo L
    Pancreatology; 2002; 2(2):163-6. PubMed ID: 12123097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients.
    Shi YF; Zhu XF; Harris AG; Zhang JX; Dai Q
    J Clin Endocrinol Metab; 1993 Jan; 76(1):32-7. PubMed ID: 8421099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sandostatin desensitization--a strategy useful for patients with carcinoid tumors, intolerant to sandostatin.
    Vinjamaram S; Iyer R
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):225-6. PubMed ID: 20922390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.